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Abstract
Background: Critical illness polyneuropathy (CIP) is a complex disease affecting 30–70% of critically ill patients.
Methods: Clinical (Barthel index, length of stay (LOS), morbidity, duration of mechanical ventilation, routine lab
results) and neurophysiological (neurography) data of 191 patients admitted to neurological early rehabilitation and
diagnosed with CIP have been analyzed retrospectively.
Results: CIP diagnosis was correct in 159 cases (83%). In this study, systemic inflammation, sepsis, systemic inflammatory
response syndrome (SIRS), multiple organic failure (MOF), chronic renal failure, liver dysfunction, mechanical ventilation,
diabetes, dyslipidemia and impaired ion homeostasis (hypocalcaemia, hypokalemia) were associated with CIP.
Neurography, in particular of the peroneal, sural, tibial and median nerves, helped to identify CIP patients.
Compound muscle action potential amplitude (r = −0.324, p < 0.05), as well as sensory (r = −0.389, p < 0.05)
and motor conduction velocity (r = −0.347, p < 0.05) of the median nerve correlated with LOS in neurological
early rehabilitation but not with outcome measures.
Conclusions: In most cases, diagnosis of CIP among neurological early rehabilitation patients seems to be
correct. Neurography may help to verify the diagnosis and to learn more about CIP pathophysiology, but it
does not allow outcome prediction. Further studies on CIP are strongly encouraged.
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Background
Among critically ill neurological or neurosurgical patients
entering early rehabilitation, critical illness polyneuropathy
(CIP) and/or myopathy (CIM) are frequent disorders. It
has been shown that CIP affects 30–70% of critical care
patients [1]. CIP is regarded as a predominantly distal,
motor and sensory axonal polyneuropathy [1] and may
contribute to a failure of weaning from mechanical venti-
lation, higher mortality and prolonged length of stay
(LOS) in hospital and rehabilitation [2–4]. CIP prevalence
in early rehabilitation is higher than in acute-care facilities
because critical care patients after failure of weaning accu-
mulate in rehabilitation centers [5, 6].
Pathophysiology of CIP is complex and involves im-
paired microcirculation (sepsis), increased expression of
E-selectin, cytokine secretion, increased cell permeabil-
ity, mitochondrial dysfunction with reduced adenosine
triphosphate synthesis (cytopathic hypoxia), damage
through neurotoxic factors (reactive oxygen species,
nitric oxide) and hyperglycemia [2, 7].
In addition, some risk factors have been identified, such
as systemic inflammatory response syndrome (SIRS), sep-
sis, multiple organ failure (MOF), age, gender, mechanical
ventilation, morbidity, renal failure, hypotension, hyper-
osmolarity, parenteral nutrition, low serum albumin,
immobilization, medication and hypoxia [2, 7–9].
Until now, there are no compulsory diagnostic criteria,
but it has been suggested to perform neurophysiological
measurements to confirm diagnosis of CIP, in particular
of the peroneal and sural nerve [10–12]. An amplitude
reduction of the compound muscle action potential
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(CMAP) of the peroneal nerve was found to be most
sensitive and specific [10].
The present study focused on clinical features and
outcome of CIP patients admitted to neurological early
rehabilitation.
Methods
Patients, who have been admitted to early rehabilitation
between 2004 and 2014, were screened for the main or
co-diagnosis of CIP (ICD-10: G62.80). Polyneuropathies
induced by alcohol, drugs or exposure to other toxic
substances (G62.1; G62.0; G62.2) were not analyzed. Se-
lected CIP cases have been carefully reviewed. Patients
with prior neuromuscular disorders such as myasthenia
gravis, amyotrophic lateral sclerosis or multiple sclerosis
were not included. Initial lab results as well as patient
clinical complexity level (PCCL), duration of mechanical
ventilation, Barthel index (BI), LOS, co-diagnoses and
colonization with multi-drug resistant germs (methicillin
resistant staphylococcus aureus and/or extended spectrum
beta-lactamase producing germs) were included in the
analysis. Colonization with these bacteria is of importance
because it has been demonstrated that it deteriorates out-
come from neurological early rehabilitation [13, 14]. In
addition, medical reports of the transferring hospital have
been reviewed with respect to duration of ventilation,
MOF (at least 2 or more dysfunctional organs) and sepsis.
Furthermore, presence of spinal lesions were verified by
existing CT or MRT images (if available) to exclude pa-
tients with palsies caused by spinal injuries. Available neu-
rography data of the tibial, peroneal, median and sural
nerve have been analyzed. For the nerve conduction
studies, surface electrodes and a Nicolet Viking Select
apparatus (Natus Medical, Middleton, WI, USA) were
used. Motor and sensory nerve conduction velocity
(CV) [m/s], distal motor latency (DML) [ms], com-
pound muscle action potential (CMAP) amplitudes
[mV] and sensory nerve action potential (SNAP) ampli-
tudes [μV] have been recorded.
CIP diagnosis was confirmed by means of neurography
and/or clinical examination (e.g. palsies, loss of tendon
reflexes, sensory involvement). The neurographical
examination was performed by an experienced medical
practitioner, who used the following reference levels for
detecting abnormal parameters: CV >40 m/sec (for tibial
and peroneal nerve) or >45 m/sec (for median nerve);
CMAP >5 mV (for tibial und median nerve) or >2 mV
(for peroneal nerve).
Statistics were performed with SPSS version 21. First,
important features were identified by descriptive statistics.
Secondly, correlation analyses using the Pearson (normal
distribution) or Spearman method (not normally distrib-
uted) were done comparing neurophysiological data
(CMAP, SNAP, CV) and clinical or laboratory findings. In
addition, the study sample was divided into two groups:
confirmed vs. non-confirmed CIP diagnosis. Differences
between these groups were analyzed by t-tests (normal
distribution) or Wilcoxon tests (not normally distributed).
P-values of less than 0.05 were regarded as statistically
significant.
Results
Among 191 patients transferred to early rehabilitation
diagnosed with CIP, 159 cases (83.2%) were confirmed
clinically (n = 103) and/or by neurography (n = 56). In 32
cases (16.8%), CIP could not be verified by neurography
(n = 2) or by clinical examinations (n = 30). Within the
clinical preclusions, patients with positive Babinski signs
(12 cases), slight strength reduction (7 cases), flabby ton-
icity (3 cases) or missing any clinical signs (8 cases) were
defined as false positives.
There were 90 men (57%) and 69 women (43%) in the
CIP verified group, aged between 28 and 86 years (mean
66 ± 11 years). During early rehabilitation, four CIP
patients died (2.5%).
Table 1 presents clinically relevant co-diagnoses of
patients with confirmed CIP. Cardiovascular diseases
and colonization with multi-drug resistant bacteria were
found to be most frequent.
Table 2 shows the lab results of patients with verified
CIP diagnosis. C-reactive protein (CRP) was elevated in
91.7% of cases. While 52.5% had a slight (≤50 mg/l),
27.0% showed a moderate (50–100 mg/l) and 12.2% a
marked elevation (>100 mg/l). 43% had been suffering
from sepsis. There was a significant correlation between
CRP and CMAP of the peroneal nerve (Table 3, r =
−0.328; p < 0.05).
MOF had occurred in 14% (n = 21) of all cases and
was associated with a CV slowing of the peroneal nerve
(p < 0.05). Consistent with the diagnosis of previous MOF,
increased urea and elevated gamma glutamyl transferase
(GGT) levels were observed (Table 2). Chronic renal fail-
ure was detected in 18% (n = 28) of all cases. Patients with
chronic renal failure were significantly older (p < 0.05),
Table 1 Co-diagnoses of patients with confirmed CIP
Co-diagnoses Prevalence (%)
Cardiovascular diseases 123 (77)
Colonization with multi-drug resistant germs 69 (43)
Type 2 diabetes 54 (34)
Hypokalemia 52 (33)
Hypoosmolarity and hyponatremia 36 (23)
Chronic renal failure 28 (18)
Hypothyreosis 23 (15)
Hyperlipidemia 14 (9)
Alcohol abuse 9 (6)
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had a higher PCCL (p < 0.01) and smaller CMAP of the
peroneal nerve (p < 0.01) than patients with normal
kidney function.
There was a negative correlation between potassium and
median nerve CMAP amplitudes (r = −0.318, p < 0.05).
While mean potassium concentration was within normal
range, sodium was decreased in about one third of cases
(Table 2) and correlated significantly with sural SNAP
amplitudes (r = 0.360, p < 0.05). As with sodium, calcium
concentrations were frequently below normal range (in
45% of cases, Table 2). Calcium correlated significantly
with peroneal nerve CMAP amplitudes (r = 0.331, p < 0.05)
as well as CV (r = 0.301, p < 0.05).
In the present study, 78.6% of CIP patients had been
on mechanical ventilation. Ventilation before or during
early rehabilitation was associated with a significantly lon-
ger LOS (p < 0.05), sepsis (p < 0.01), SIRS (p < 0.01) and
clinical sensory disturbances (p < 0.05). In addition, dur-
ation of ventilation (in hours) correlated negatively with
median nerve CMAP amplitudes (r = −0.293, p < 0.05),
motor (r = −0.538, p < 0.001) and sensory CV (r = −0.516,
p < 0.001). Monocytes (p < 0.05), leucocytes (p < 0.01),
neutrophils (p < 0.05), potassium (p < 0.01), urea (p < 0.01)
and GGT levels (p < 0.05) were elevated in ventilated com-
pared to spontaneously breathing patients.
Fasting glucose levels were increased in the study sam-
ple (Table 2) and correlated negatively with peroneal
CMAP amplitudes (r = −0.306, p < 0.05, Table 3). Dia-
betic patients (type 1 (n = 2), type 2 (n = 52), Table 1)
had reduced CMAP (p < 0.05) and SNAP amplitudes of
Table 2 Admission lab results of patients with confirmed CIP
Lab results Mean SD Normal
range
Proportion of lab results [%]
Above normal range Below normal range
Sodium [mmol/l] 137.78 4.78 136–145 28% ↓
Potassium [mmol/l] 4.03 0.70 3.50–5.00
Calcium [mmol/l] 2.16 0.33 2.15–2.80 45% ↓
Chlorid [mmol/l] 100.87 5.50 97–108
Glutamat oxalacetat transaminase [U/l] 31.95 22.70 <50
Glutamat pyruvat transaminase [U/l] 38.55 37.70 <50
Gamma glutamyl transferase [U/l] 233.17 326.21 <55 71% ↑
Cholinesterase [U/l] 5750.81 2416.25 4000–13000
Total protein [g/dl] 6.70 0.82 6.6–8.3
Albumine [g/dl] 2.38 0.59 3.4–5.0
Creatinine [mg/dl] 0.91 0.47 0.8–1.4 23% ↑ 31% ↓
Urea [mg/dl] 41.16 35.08 3.6–7.2 100% ↑
High density lipoprotein [mg/dl] 33.50 13.23 35.0–60.0 63% ↓
Low density lipoprotein [mg/dl] 96.48 34.81 0.0–190.0
Total cholesterol [mg/dl] 167.77 45.79 <200
Triacylglycerol [mg/dl] 184.54 96.78 <150 62% ↑
Lipase [U/l] 263.31 222.30 73–393
Glucose [mg/dl] 124.70 42.83 70–110 50% ↑
C-reactive protein [mg/l] 74.75 331.56 <6 92% ↑
Trijodthyronin GT3 [ng/ml] 0.75 0.28 0.70–1.90
free Trijodthyronin FT3 [pg/ml] 2.17 0.67 2.18–3.98
free Tetrajodthyronin FT4 [ng/dl] 1.23 0.36 0.60–1.50
Thyreotropin [mU/l] 2.40 4.21 0.34–4.82
White blood cells [10^3/μl] 9.91 4.39 4.0–10.0
Red blood cells [10^6/μl] 3.61 0.54 4.40–5.90
Platelets [10^3/μl] 336.81 133.48 150–450
Lymphocytes [10^3/μl] 1.79 0.93 1.5–3
Monocytes [10^3/μl] 0.86 0.51 0.28–0.5
Neutrophils [10^3/μl] 7.14 4.09 3.2–6.2
Values out of the normal range are highlighted in bold. ns = not significant
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the median nerve (p < 0.01). In addition, diabetic patients
showed increased triacylglyceride (TG) levels (p < 0.05).
In the whole study sample, mean TG level were in-
creased (Table 2) and high density lipoproteine (HDL)
levels were frequently decreased (Table 2) correlating
with CMAP amplitudes of the tibial nerve (r = 0.372, p <
0.05). Total cholesterol levels (TC) showed a significant
correlation with CMAP amplitudes of the median nerve
(r = −0.352, p < 0.05) and levels of lipase correlated with
motor CV of the median nerve (r = −0.285, p < 0.05,
Table 3). Nevertheless, disturbance of lipoprotein metab-
olism was also associated with reduced number of leuko-
cytes (p < 0.05), thrombocytes (p < 0.05) and neutrophils
(p = 0.026) as well as reduced SNAP amplitudes of the
median nerve (p < 0.05). In contrast, creatinine level
(p < 0.01) was increased.
Outcome and prognosis of patients with confirmed
CIP was not different from patients without neur-
opathy. In addition, Barthel index (BI) on admission, at
discharge and BI changes (discharge minus admission)
did not show any significant correlation with neuro-
physiological data.
LOS in neurological early rehabilitation correlated sig-
nificantly with CMAP (r = −0.324, p < 0.05), motor (r =
−0.347, <0.05) and sensory CV (r = −0.389, p = 0.004) of
the median nerve.
Discussion
The current study focused on clinical and nerve conduc-
tion features of critically ill patients diagnosed with CIP.
While literature findings suggest that female gender
might be an independent risk factor for CIP [15], there
were no significant clinical or neurophysiological differ-
ences between men and women. Mortality in our study
(2.5%) was in line with previous results from a literature
review suggesting no increase of unadjusted mortality in
critical ill patients with neuromuscular abnormalities [9].
However, other studies revealed a higher mortality be-
tween 21 and 55% among CIP and CIM patients [10–12],
in particular with coincident sepsis [16, 17].
Confirmed risk factors for CIP are sepsis, SIRS and MOF
[7, 11, 18–20]. CRP, a marker for SIRS [21] and sepsis
[22, 23], were increased in nearly all cases of the present
study, indicating systemic inflammation. Incidence of sep-
sis (n = 68; 43%) was higher than reported rates in other
studies [11]. We found a significant negative correlation
between CRP and CMAP amplitudes of the peroneal nerve
suggesting that nerve damage might be related to inflam-
matory mechanisms. One reason for this correlation could
be the fact that the peroneal nerve shows most sensitivity
for CIP diagnosis [10] and therefore most sensitivity for in-
flammatory processes. MOF (n = 21; 14%) was associated
with decreased motor CV of the peroneal nerve.
Table 3 Correlations between neurography and lab results among patients with confirmed CIP
Lab result Peroneal nerve sural nerve Tibial nerve Median nerve








CRP p = 0.018
r = −0.328a
ns ns ns ns ns ns
HDL ns ns ns p = 0.047
r = 0.372b
ns ns ns
TC ns ns ns ns p = 0.011
r = −0.352b
ns ns
Lipase ns ns ns ns ns p = 0.044
r = −0.285
ns
Glucose p = 0.028
r = −0.306a
ns ns ns ns ns ns
Red blood cells ns ns ns ns p = 0.025
r = 0.310b
ns ns




ns ns ns ns ns
Potassium ns ns ns ns p = 0.022
r = −0.318b
ns ns
Sodium ns ns p = 0.011
r = 0.360b
ns ns ns ns
Chlorid ns ns p = 0.01
r = 0.374b
ns ns ns ns
Creatinin ns ns ns ns ns ns p = 0.034
r = −0.295a
aCorrelation analysis by Spearman (not normal distributed data), bCorrelation analysis by Pearson (normal distribution)
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Consistent with MOF, increased uric acid, decreased
creatinine and elevated gamma glutamyl-transferase
(GGT) levels indicating renal and liver dysfunction were
observed in the current study. Chronic renal failure were
detected in 18% (n = 28) of all cases, which was twice as
much than reported previously [11]. In addition, patients
with chronic renal failure were older, exhibited higher
morbidity (PCCL) and had reduced CMAP amplitudes
of the peroneal nerve in our study. In this case, reduced
CMAP of peroneal nerve could be caused by toxic ef-
fects of uremic toxins upon the nerve axon membrane
and not necessarily by CIP. However, it has been hy-
pothesized that renal damage raises level of endoneurial
potassium (even though serum potassium levels stay in
normal range), affecting slow potassium channels and
leading to membrane depolarization and pathogenesis of
CIP [1]. In line with this finding, the present study dem-
onstrated significant negative correlations between potas-
sium level and median nerve CMAP amplitudes (p < 0.05).
In healthy volunteers, a high potassium level was associ-
ated with lower excitability of the median nerve [24, 25].
Moreover, membrane depolarization and pathogenesis of
CIP may be induced by hyperkalemia [26, 27]. While po-
tassium level was within normal range, sodium level was
increased in this study and significantly correlated with
SNAP amplitudes of the sural nerve.
With respect to ion homeostasis, hyper- but in particu-
lar hypocalcemia are independent risk factors for CIP [28].
In this study, calcium levels were below normal. Further-
more, calcium levels correlated with peroneal CMAP am-
plitudes and motor CV. These findings suggest that
hypocalcemia might play a role in the pathophysiology of
CIP, probably by changes of membrane polarization [29].
It is known that mechanical ventilation is associated
with CIP [9, 18]. In this study, 79% of all patients had
been on mechanical ventilation before or during early
rehabilitation. Ventilation was associated with a longer
LOS (p < 0.05), which is in line with a previous study
[11]. In addition, ventilated patients suffered from sep-
sis (p < 0.01), SIRS (p < 0.01) and sensory impairment
(p < 0.05) more frequently. The longer the patients were
on mechanical ventilation, the smaller were the re-
corded CMAP amplitudes and the lower were the
motor and sensory CV of the median nerve. This find-
ing supports the hypothesis that ventilation is a risk
factor for the emergence of CIP [9].
Diabetes mellitus is a common cause of polyneurop-
athy [30, 31] and might confound findings of CIP. Fast-
ing glucose levels were elevated in the study sample
and correlated with peroneal CMAP amplitudes.
Hyperglycemia as a result of reduced insulin produc-
tion caused by increased glucagon synthesis (postagres-
sion metabolism) might be one explanation for the
increased glucose levels. However, it should be taken
into account that the postagression phase is normally
observed within the fourth to seventh day after acute
event and not during rehabilitation. In addition, there
were reduced median nerve CMAP and SNAP among
diabetic patients suggesting that the median nerve
should be examined additionally to confirm CIP diag-
nosis in diabetic patients.
In line with previous studies, diabetic patients showed
increased triacylglyceride (TG) [32, 33]. It is unclear
whether dyslipidemia may be a risk factor for CIP. In the
current study, high density lipoproteine (HDL) levels
were below normal and correlated positively with tibial
nerve CMAP amplitudes. Reduced HDL level are associ-
ated with immobility, which is associated with CIP.
Therefore, a relationship between HDL and reduced
CMAP of tibial nerve is maybe caused by immobility.
Other studies discovered prevalence of hypercholesterol-
emia [19] and increased TG level [34]. In the current
study, TC correlated negatively with CMAP of the me-
dian nerve. It remains unclear why the correlation was
detected only in the median and not in the peroneal
nerve. Maybe the median nerve is specific for hyperchol-
esterolemia. Other studies demonstrated elevated total
cholesterol levels in patients with carpal tunnel syn-
drome and reported that hypercholesterolemia is an in-
dependent risk factor [35, 36]. Therefore, a direct causal
link between CIP and increased total cholesterol levels
probably is non-existent. However, the role of lipid me-
tabolism is a matter of controversial discussion [37].
CIP is regarded as a predominantly axonal polyneur-
opathy [1], but there was also evidence for a demyelinat-
ing nerve impairment (CV reduction) in our study.
Confounding diagnoses like diabetes might account for
this phenomenon and it is difficult to extrapolate these
influences. However, given the broad spectrum of risk
factors in CIP, it would be surprising to find nothing but
axonal nerve damage. The results from our study sug-
gest that primary or secondary demyelinating processes
may occur in CIP, too.
Clinical neurophysiology, in particular evoked poten-
tials, may be helpful to predict outcome of early rehabili-
tation patients [38–40]. However, neurography data of
CIP patients did not correlate with any of the outcome
measures. While duration of mechanical ventilation had
an influence on the extent of axonal and demyelinating
nerve damage, neurography did not predict functional
independence of CIP patients.
Most frequently, neurography of peroneal and sural
nerves have been analyzed in CIP [10–12]. Our data
confirmed the importance and sensitivity of peroneal
nerve measurements [10]. However, results from our
study suggest that examination of tibial and, in particu-
lar, median nerve conduction may be of importance
wheninvestigating CIP pathophysiology, too.
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Limitations
The study has some limitations. First, since the CIP
diagnosis was confirmed mainly by clinical examination,
the number of false positive diagnoses could be underes-
timated. However, in clinical settings, the diagnosis of
CIP is usually confirmed through clinical examinations
performed by experienced physicians. In addition, CIP
and CIM often occur together and cases with a combin-
ation of CIP/CIM pathogenesis cannot be excluded. Al-
though electromyography and nerve conduction studies
provide a bedside method to confirm the diagnosis, rou-
tine electrophysiological examination cannot discriminate
between CIP and CIM in critically ill, sedated, uncoopera-
tive, or extremely weak patients. A differentiation of CIP
and CIM is only possible in adequately awake and co-
operative patients, which is often in contrast to the state
of consciousness of our patients. Therefore, the main diag-
nosis is made by clinical examination. However, the clin-
ical relevance of differentiating between neuropathy and
myopathy is still under debate, because the outcome prog-
nosis is almost the same. A strict separation of CIP and
CIM is only possible via muscle biopsy, which is rarely
performed in daily clinical practice. Due to the study de-
sign (retrospective analysis of routinely collected data)
muscle biopsies were performed only in some cases. Sec-
ond, no temperature recording was performed during
neurography measurement and reference values were not
age-adjusted, which could have slight effects on the
NC. Third, only patients with CIP main or co-diagnosis
were investigated in the study. A comparison with age-
and sex-matched patients with similar Barthel-Index, co-
diagnosis and central lesions, e.g. the main ICD-10 diag-
nosis I63, would be an important benefit for the quality of
the study.
Conclusions
CIP is a complex disease with a broad spectrum of risk
factors, but pathophysiology is still unclear. The current
study supports the hypothesis that sepsis, SIRS, MOF,
chronic renal failure, liver dysfunction, mechanical venti-
lation, diabetes, dyslipidemia, systemic inflammation and
impaired ion homeostasis (hypocalcaemia, hypokalemia)
are associated with CIP. Neurophysiological examina-
tions of peroneal, sural, tibial and median nerves may
help to study CIP pathophysiology and to confirm diag-
nosis, but they do not predict outcome.
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